No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
Corporate Compliance Insights
Home Compliance

The Latest Trends in the Russian Clinical Trials Process from an Anticorruption Standpoint

by Michael A. Tooshi
November 5, 2014
in Compliance
The Latest Trends in the Russian Clinical Trials Process from an Anticorruption Standpoint

with contributing author Jon Umarov 

This article originally appeared on Michael Tooshi’s FCPA-RUCIS blog and is republished here with permission.

In recent years, clinical trials in Russia have become increasingly common for western pharmaceutical companies and in our opinion, the pharmaceutical sector’s continued development in Russia represents a trend that is set to continue despite the exchange of sanctions between Russia and western governments as a result of the conflict in Ukraine. For example, in 2013, the European Medicines Agency reported that between 2005 and 2011, 62 percent of patients for use in clinical trials were recruited outside the EU and Switzerland, with increasingly prevalent trends in the Commonwealth of Independent States (CIS). The usage of patients from the region rose from less than 1 percent in 2005 to 7.5 percent by 2011. The Center for Drug Evaluation and Research (CDER) of the FDA approved 25 new drugs during Q2 2014, and 10 of them were (or are currently) under study in clinical trials conducted in Russia. According to the latest Orange Paper by the Synergy Research Group, a major clinical trials organization in Russia, the share of multinational, multicenter clinical trials was 42 percent of the total number of clinical trials in Q2 2014, and bioequivalence and local studies amounted to 30 percent and 28 percent respectively.

According to the same report, in Q2 2014, clinical trials in Russia were sponsored by companies from 24 countries. The highest number of trials (89) was initiated by Russian sponsors. American sponsors took the runner-up place, with 29 new studies; they are followed by German and UK sponsors with 11 trials each, Swiss sponsors with 10 studies and Israeli sponsors with nine new studies. The group of leaders is concluded by French sponsors, having seven studies.

The number of Phase I clinical trials remained about the same and stood at eight new studies in Q2 2014. The number of the Phase II trials increased from 21 in Q2 2013 to 29 new studies in Q2 2014. The number of Phase III trials increased from 88 to 92 studies, 5 percent more than in Q2 2013. Phase IV trials showed an increase from five studies in Q2 2013 to six studies in Q2 2014. The number of subjects planned to be enrolled in Phase I to IV trials launched in Q2 2014 is 15,424, representing 22 percent more than in Q2 2013 figure, when 12,677 patients were planned to be enrolled.

Turning to the legal framework in Russia, the Federal Law on “Circulation of Medicines” governs most aspects of clinical trials in the country. The Ministry of Health (or Ministerstvo Zdravoohraneniya) is responsible for regulating the clinical trials process, along with the Federal Service on Surveillance in Healthcare (or Roszdravnadzor), which oversees the safety and registration of medical drugs. Clinical trials in the country are conducted in accordance with Executive Order No. 266 on the “Rules for Clinical Practice in the Russian Federation,” dated June 2003, in conjunction with the “National Standards of GCP in the Russian Federation,” established in 2005.

The Ministry of Healthcare has also issued a series of orders governing the clinical trials process. Under the Law on the “Circulation of Medicines,” medical drugs must be tested in a clinical trial before they can be marketed and sold in Russia. Such requirements apply to any medicines, even if they have already undergone a clinical trial in another country. This requirement has led to increased numbers of multicenter and bio-equivalence studies for drugs that are destined for the Russian pharmaceutical market.

Additionally, medication manufactured abroad cannot undergo its first clinical trial in Russia, a regulatory requirement creating the need for testing the medicine in another state prior to its introduction in Russia, usually the country of manufacture. The requirement serves as an incentive for companies to localize their manufacturing process and serves to bring the clinical trials sector into line with the objectives of Russia’s Pharma 2020 strategy, announced in 2009.

According to the Ministry of Healthcare, clinical trials may be conducted by pharmaceutical companies either directly or through the engagement of a third-party “contract research organization” (CRO). The types of trials can be broken down into International Multicenter Clinical Trials (or IMCTs), local trials of efficacy and safety and bio-equivalence studies. Local trials and bioequivalence studies can be arranged by both local and foreign-based sponsors.

In order to conduct a clinical trial, a sponsor must submit an application to the Scientific Center for the Evaluation of Products for Medical Use and also have it approved by the Ethics Council of the Ministry of Healthcare. The Law on the “Circulation of Medicines” forbids direct interaction between the Ethics Council and pharmaceutical companies. Some have cautioned that this apparent anti-corruption measure is too strict, and has only served to increase the number of applications that are not approved due to technicalities owing to the fact that constructive scientific dialogue between the authorities and manufacturers has become more challenging to achieve.

International investors in Russia should be aware of corruption risks associated with the process in Russia, in addition to familiarizing themselves with the Law on “Circulation of Medicines” and all applicable regulations on clinical trials in Russia. Interactions with public officials are inevitable in clinical trials. FCPA-RUCIS would like to emphasize that although engaging CROs to assist with clinical trials can make navigating the process easier, it could also lead to third-party risks when attempting to overcome the inevitable procedural hurdles in Russia.


Previous Post

The Future of Data Analytics: From Cleaning Up the Trash to Managing Risk

Next Post

Two Secrets to Fighting Company Card Fraud

Michael A. Tooshi

Michael A. Tooshi

Michael Tooshi is an attorney based in the Washington, D.C. area with experience involving anti-corruption and compliance issues.

Related Posts

boris johnson resigns as UK prime minister

Report: Most Countries Failing to Stop Corruption

by Staff and Wire Reports
February 2, 2023

Denmark remained the least corrupt country in the world for the fifth year running, according to the recently released Transparency...

exec fired

44% of Companies Say They’ve Disciplined Execs for Ethics Breaches

by Staff and Wire Reports
February 2, 2023

More than two-fifths of companies (44%) say they have fired or disciplined senior leadership for unethical conduct in the past...

clausematch ai

Clausematch Releases Knowledge Graph to Drive Digitization of Regulation With AI

by Corporate Compliance Insights
February 2, 2023

Global RegTech provider Clausematch has released its digital knowledge graph in open source, allowing regulators and financial service companies to...

logicgate_climbchannel

LogicGate Hopes to Expand RiskCloud’s EMEA Reach

by Corporate Compliance Insights
February 2, 2023

Risk and compliance provider LogicGate is expanding its international presence thanks to a new partnership with Climb Channel Solutions, a...

Next Post
Two Secrets to Fighting Company Card Fraud

Two Secrets to Fighting Company Card Fraud

Compliance Job Interview Q&A

Jump to a Topic

AML Anti-Bribery Anti-Corruption Artificial Intelligence (AI) Automation Banking Board of Directors Board Risk Oversight Business Continuity Planning California Consumer Privacy Act (CCPA) Code of Conduct Communications Management Corporate Culture COVID-19 Cryptocurrency Culture of Ethics Cybercrime Cyber Risk Data Analytics Data Breach Data Governance DOJ Download Due Diligence Enterprise Risk Management (ERM) ESG FCPA Enforcement Actions Financial Crime Financial Crimes Enforcement Network (FinCEN) GDPR HIPAA Know Your Customer (KYC) Machine Learning Monitoring RegTech Reputation Risk Risk Assessment SEC Social Media Risk Supply Chain Technology Third Party Risk Management Tone at the Top Training Whistleblowing
No Result
View All Result

Privacy Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2022 Corporate Compliance Insights

No Result
View All Result
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe

© 2022 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT